2',3'-Dideoxyinosine
Suppliers
Names
[ CAS No. ]:
69655-05-6
[ Name ]:
2',3'-Dideoxyinosine
[Synonym ]:
9-[(2R,5S)-5-(hydroxyméthyl)tétrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
DDI
Videx
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydro-2-furanyl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-9H-purin-6-ol
MFCD00077728
Inosine, 2’,3’-dideoxy-
VIDEX EC
2',3'-Dideoxyinosine
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
6H-Purin-6-one, 1,9-dihydro-9-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-
INOSINE, 2',3'-DIDEOXY-
Dideoxyinosine
Didanosine
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-on
didanosinum [INN_la]
Chemical & Physical Properties
[ Density]:
1.8±0.1 g/cm3
[ Boiling Point ]:
531.2±60.0 °C at 760 mmHg
[ Melting Point ]:
193-195 °C
[ Molecular Formula ]:
C10H12N4O3
[ Molecular Weight ]:
236.227
[ Flash Point ]:
275.0±32.9 °C
[ Exact Mass ]:
236.090942
[ PSA ]:
93.03000
[ LogP ]:
-1.31
[ Vapour Pressure ]:
0.0±1.5 mmHg at 25°C
[ Index of Refraction ]:
1.798
[ Storage condition ]:
2-8°C
[ Stability ]:
Stable. Combustible. Incompatible with strong oxidizing agents.
[ Water Solubility ]:
1-5 g/100 mL at 21 ºC
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- NM7460700
- CHEMICAL NAME :
- Inosine, 2',3'-dideoxy-
- CAS REGISTRY NUMBER :
- 69655-05-6
- LAST UPDATED :
- 199803
- DATA ITEMS CITED :
- 7
- MOLECULAR FORMULA :
- C10-H12-N4-O3
- MOLECULAR WEIGHT :
- 236.26
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 2340 mg/kg/34W-I
- TOXIC EFFECTS :
- Liver - fatty liver degeneration Liver - jaundice, cholestatic Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 28 gm/kg/28D-I
- TOXIC EFFECTS :
- Immunological Including Allergic - decrease in humoral immune response
MUTATION DATA
- TEST SYSTEM :
- Rodent - mouse
- DOSE/DURATION :
- 6 gm/kg/3D (Intermittent)
- REFERENCE :
- EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991
Safety Information
[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
[ Hazard Codes ]:
C
[ Risk Phrases ]:
R34
[ Safety Phrases ]:
S26-S27-S36/37/39-S45
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
2
[ RTECS ]:
NM7460700
[ HS Code ]:
2942000000
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2942000000
Articles
Antimicrob. Agents Chemother. 51 , 2531-9, (2007)
Nucleoside analogs are associated with various mitochondrial toxicities, and it is becoming increasingly difficult to accommodate these differences solely in the context of DNA polymerase gamma inhibi...
Chem. Res. Toxicol. 23 , 171-83, (2010)
Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental...
J. Sci. Ind. Res. 65(10) , 808, (2006)
Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ...